Norbert W. Marschner

Freiburg, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 83 publications

Tumor Genomic Profiles Associated with Clinical Benefit from Immune Checkpoint Inhibitor Therapy - An Exploratory Analysis of the INFINITY Precision Oncology Registry.

Tumor Genomic Profiles Associated with Clinical Benefit from Immune Checkpoint Inhibitor Therapy - An Exploratory Analysis of the INFINITY Precision Oncology Registry.

Journal: OncoTargets and therapy

Published: April 01, 2026

First-Line Treatment with Tivozanib for Metastatic Renal Cell Carcinoma in Real-World Settings Across Germany: Results of the Prospective, Non-Interventional, Post-Approval Study T-Rex.

First-Line Treatment with Tivozanib for Metastatic Renal Cell Carcinoma in Real-World Settings Across Germany: Results of the Prospective, Non-Interventional, Post-Approval Study T-Rex.

Journal: Cancers

Published: October 16, 2025

Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR-positive/HER2-negative metastatic breast cancer: Real-world data from the OPAL registry.

Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR-positive/HER2-negative metastatic breast cancer: Real-world data from the OPAL registry.

Journal: International journal of cancer

Published: August 06, 2025

Correction to: Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis.

Correction to: Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis.

Journal: Current oncology reports

Published: May 09, 2025

Prospective validation of the modified metastatic colorectal cancer score (mCCS) in >600 patients with RAS-wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE.

Prospective validation of the modified metastatic colorectal cancer score (mCCS) in >600 patients with RAS-wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE.

Journal: International journal of cancer

Published: January 28, 2025

Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis.

Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis.

Journal: Current oncology reports

Published: October 05, 2024

Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B Trial.

Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B Trial.

Journal: Oncology research and treatment

Published: September 19, 2024

Changes in survival of >3800 patients with metastatic colorectal cancer in Germany: results from a 16-year prospective longitudinal real-world data analysis.

Changes in survival of >3800 patients with metastatic colorectal cancer in Germany: results from a 16-year prospective longitudinal real-world data analysis.

Journal: ESMO real world data and digital oncology

Published: May 07, 2024

Ambulatory Routine Care in Oncology in Germany: Real-World Survival Data.

Ambulatory Routine Care in Oncology in Germany: Real-World Survival Data.

Journal: Oncology research and treatment

Published: December 29, 2023

Head-to-head comparison of treatment sequences in advanced pancreatic cancer-Real-world data from the prospective German TPK clinical cohort study.

Head-to-head comparison of treatment sequences in advanced pancreatic cancer-Real-world data from the prospective German TPK clinical cohort study.

Journal: International journal of cancer

Published: December 20, 2023

Quantifying bias due to missing data in quality of life surveys of advanced-stage cancer patients.

Quantifying bias due to missing data in quality of life surveys of advanced-stage cancer patients.

Journal: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation

Published: December 11, 2023

Final Results from RIBBIT: A Randomized Phase III Study to Evaluate Efficacy and Quality of Life in Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Receiving Ribociclib in Combination with Endocrine Therapy or Chemotherapy with or without Bevacizumab in the First-Line Setting.

Final Results from RIBBIT: A Randomized Phase III Study to Evaluate Efficacy and Quality of Life in Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Receiving Ribociclib in Combination with Endocrine Therapy or Chemotherapy with or without Bevacizumab in the First-Line Setting.

Journal: Breast care (Basel, Switzerland)

Published: September 25, 2023

Showing 1-12 of 83

Last Updated: 09/26/2026